To tackle superbug scourge and revive R&D, incentivize FDA antibiotic approvals — drugmakers, health groups urge US lawmakers
As superbugs flourish, the industry players contributing to the arsenal of antimicrobials are dwindling. Drugmakers are enticed by greener pastures, compared to the long arduous path to antibiotic approval that offers little financial gain as treatments must be priced cheaply, and often lose potency over time as microbes grow resistant to them. For one of the biggest threats to global health, the lion’s share of antibiotic development is taking place in a handful of labs of small biopharma companies as their larger counterparts focus on more lucrative endeavors. Existing incentives to entice antibiotic R&D are too feeble to fix this broken system, a group of drugmakers, public health organizations and doctors said in a letter to US lawmakers on Tuesday, urging Senators to take a fresh approach to stimulate antimicrobial drug development by enacting policy measures to increase the value of a marketed antibiotic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.